Wegovy has been approved for use among the growing number of Americans who have MASH. By Dani Blum The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The combination of ervogastat plus clesacostat was more effective at resolving metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in patients with biopsy-confirmed MASH ...

In adults with metabolic dysfunction-associated steatohepatitis (MASH), 20 weeks of moderate-intensity aerobic exercise led to disease resolution more than twice as often as standard care, as well as ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...